350 related articles for article (PubMed ID: 27741505)
1. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
2. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
4. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
6. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
7. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
11. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
[TBL] [Abstract][Full Text] [Related]
12. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
13. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
[TBL] [Abstract][Full Text] [Related]
14. Biallelic
Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
[TBL] [Abstract][Full Text] [Related]
15. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing.
Mollica V; Franceschini T; Gruppioni E; Rizzo A; Ricci C; Schiavina R; Brunocilla E; Ardizzoni A; Fiorentino M; Giunchi F; Massari F
Pathol Res Pract; 2021 Mar; 219():153350. PubMed ID: 33556910
[TBL] [Abstract][Full Text] [Related]
16. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
Alsidawi S; Kasi PM
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
18. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
20. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations?
Parilla M; Kadri S; Patil SA; Ritterhouse L; Segal J; Henriksen KJ; Antic T
Am J Surg Pathol; 2018 Jul; 42(7):911-917. PubMed ID: 29668487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]